Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

Smit, E F

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Jul 2012 - 1723-9 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdr563 doi


Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor--genetics
Carboplatin--administration & dosage
Clinical Trials, Phase III as Topic
Collagen Type XVIII--genetics
DNA-Binding Proteins--metabolism
Disease-Free Survival
Endonucleases--metabolism
Etoposide--administration & dosage
Glutamates--administration & dosage
Guanine--administration & dosage
Humans
Kaplan-Meier Estimate
Logistic Models
Lung Neoplasms--drug therapy
Methylenetetrahydrofolate Reductase (NADPH2)--genetics
Pemetrexed
Peptide Synthases--genetics
Phosphoribosylglycinamide Formyltransferase--metabolism
Polymorphism, Single Nucleotide
Randomized Controlled Trials as Topic
Reduced Folate Carrier Protein--genetics
Small Cell Lung Carcinoma--drug therapy
Thymidylate Synthase--metabolism